Did Vicarious Surgical beat or miss consensus estimates last quarter?

What is Vicarious Surgical's latest dividend and current dividend yield?

What is Vicarious Surgical's gross profit margin?

What is the revenue and EPS growth rate for Vicarious Surgical year over year?

What were the key takeaways from Vicarious Surgical’s earnings call?

What is the market's earnings forecast for Vicarious Surgical next quarter?

What were the key takeaways from Vicarious Surgical's earnings call?

What does Vicarious Surgical do and what are its main business segments?

- **2026 Design Freeze On Track**: Despite 15% workforce reduction, maintaining clinical trial timelines via targeted outsourcing.
- **$10M+ Annualized Cost Savings**: 35% YoY expense reduction, with 2026 burn target <$40M.
- **Surgeon-Tested Efficiency**: 65% reduction in complex surgical procedures, validating commercial viability.
- **Transparency Boost**: Weekly LinkedIn updates to replace quarterly earnings calls for real-time progress.

**【CEO Summary Section】**
- **Design Freeze Milestone**: Targeting completion of production-equivalent system by end-2026, with focus on maintaining clinical trial and commercialization timelines despite restructuring efforts.
- **Cost Reduction Strategy**: 15% headcount reduction across non-core functions, engaging PA Consulting for outsourcing RFPs to reduce 2026 cash burn by ~$10M+.
- **Transparency Initiative**: Launching weekly LinkedIn updates on control builds (e.g., PDV2 progress), quality management system implementation, and surgeon testing results (e.g., 65% reduction in IPOM hernia suturing time from 40min to 14min).

**【CFO Financial Commentary】**
- **Q3 2025 Financials**: 
  - Total operating expenses: $11.5M (35% YoY decline)
  - GAAP net loss: $11.1M ($1.86/share) vs. $17.1M ($2.90/share) prior year
  - Cash burn rate: $10.5M/Q3, with $5.9M raised in Oct registered direct offering
- **Expense Optimization**: R&D down 28% YoY, G&A down 45%, sales & marketing down 71%.

**【Q&A Key Highlights】**
- **Outsourcing Impact**: Consulting engagement to complete by end-Nov, with RFPs for capital equipment outsourcing to begin Q1 2026.
- **Surgeon Testing Success**: 10+ surgeons tested system stability, with dramatic improvement in suturing efficiency (40min → 14min).
- **Hospital Partnerships**: Strong engagement with health systems, with surgeons requesting hands-on demos post-commercialization.

Vicarious Surgical Inc. (RBOT) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

RBOT

RBOT fundamentals

You can ask Aime